
https://www.science.org/content/blog-post/maybe-not-improved-definitely-new
# Maybe Not Improved, But Definitely New (Nov 2007)

## 1. SUMMARY

The article presents a first-person account from a medicinal chemist in the pharmaceutical industry celebrating the novelty of new compound classes that extend beyond the incremental novelty generally sufficient for patenting. The author recounts the satisfaction of synthesizing molecules that have never previously existed, drawing a contrast with routine patent-driven work where modest structural changes secure intellectual property. The piece emphasizes exploratory chemistry beyond what has already been exemplified, with the author poised to investigate compound classes for which no precedents exist. The essay captures the intrinsic motivation behind exploratory science—the desire to discover unknown structures and reaction behaviors—while acknowledging the practical reality that many attempts may yield "gooey dark stuff" and fail.

## 2. HISTORY

Drug discovery practices shifted considerably in the years following 2007, with industry R&D productivity becoming a widely discussed challenge and failure rates remaining high. Early enthusiasm for large-scale, combinatorial screening libraries—the "crank out thousands upon thousands of compounds" approach—witnessed diminishing returns, with recognition that mere novelty did not reliably translate to quality leads or clinical success.

One significant evolution was the transition toward targeted design and back-to-basics emphasis on molecular property quality. Campaigns such as PAINS (Pan Assay Interference Compounds) identification and elimination gained traction, acknowledging that certain "novel" chemotypes were liabilities—many would indeed produce the "gooey dark stuff" in terms of assay artifacts rather than genuine on-target pharmacology. Fragment-based drug discovery (FBDD) matured, often starting from smaller, well-characterized scaffolds; DNA-encoded library (DEL) technologies scaled synthesis and screening but with heightened focus on structure–activity relationships and validation.

Regulatory and clinical outcomes underscored the difficulty of true innovation versus novelty; for example, kinase inhibitors and immune checkpoint modulators demonstrated pathways in which targets proved fruitful, while many highly novel chemical series failed at Phase II and III due to efficacy or safety. Business outcomes reflected these trends: large pharma portfolios de-risked by licensing or acquiring validated chemical matter, and biotechs specializing in more rational design and translational medicine gained prominence.

Public policy saw the rise of expedited approval pathways, including breakthrough therapy designation, emphasizing unmet need and clinical impact over purely chemical novelty. The decade-plus following 2007 did not render medicinal chemistry obsolete, but it tempered the notion that sheer volume of novel patents equates to progress, favoring more strategic programs built around validated biology and drug-like property design.

## 3. PREDICTIONS

- **No explicit predictions**: The author does not make firm predictions about future outcomes or industry directions. The piece is largely retrospective and personal—recounting past experiences—and aspirational about upcoming exploratory work. Consequently, there are no concrete forecasts to compare against future developments. The article is less concerned with forecasting than with articulating the intrinsic motivation behind pushing into unknown chemical space.

## 4. INTEREST

Rating: **4/10**

The article captures the day-to-day ethos of medicinal chemistry and conveys authentic research motivation, but it offers limited forward-looking analysis or concrete outcomes, instead functioning as a personal reflection on novelty in chemical synthesis.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20071115-maybe-not-improved-definitely-new.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_